Viking Therapeutics Action
ActionActionPrix
Questions fréquentes
Quelle est la capitalisation boursière de Viking Therapeutics ?
Quel est le bénéfice par action (BPA) de Viking Therapeutics ?
Quelles sont les évaluations des analystes et le prix cible de l'action Viking Therapeutics ?
Quel est l'EBITDA de Viking Therapeutics ?
Quel est le flux de trésorerie disponible de Viking Therapeutics ?
Quel est le bêta à 5 ans de l'action Viking Therapeutics ?
Combien d'employés compte Viking Therapeutics, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Viking Therapeutics ?
Finances
Capitalisation boursière
8,08 Md $USbêta sur 5 ans
0,99BPA (TTM)
-0,937 $USFree Float
104,07 MEBITDA (TTM)
-133,97 M $USCash-flow disponible (TTM)
-74,25 M $USCotation
Notes des analystes
L'objectif de prix est de 114,20 $US et l'action est analysée par 11 analystes.
Acheter
11
Hold
0
Vendre
0
Informations
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.
33
Biotechnology & Drugs
Soins de santé
Identifiant
ISIN
Ticker primaire